Lead CF Drug Fails Phase 2a, Sionna Stock Crashes 92%
SION is trading near its 52-week low of $4.01 (9.9% above the low) on elevated volume (33× avg).
Summary
Sionna's lead cystic fibrosis drug, SION-719, missed its primary endpoint in the Phase 2a PreciSION CF trial, showing a -1.0 mmol/L placebo-adjusted change in sweat chloride (p=0.7) — essentially no activity. The company is discontinuing the program entirely. This follows the 8-K filed earlier today and the Dow Jones report at 13:07, but the stock's 92% plunge to $4.86 is a new, massive repricing. The company will conserve cash, but with the lead asset gone, the pipeline now hinges on early-stage dual combinations (SION-451 with SION-2222 selected as preferred regimen) that are years from pivotal data. The $250M ATM shelf and recent insider selling add pressure. The next catalyst is unclear — the remaining programs are preclinical or Phase 1, and the cash runway into 2028 may now be at risk if spending isn't drastically cut.
At the time of this announcement, SION was trading at $4.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $4.01 to $54.97. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Benzinga.